| Lixiu Zhu,Jiawen Yan,Guoqiang Xu,Qiaoli Wang,Tianrui Xu,Ruixue Cao,Chuanzheng Sun,Yan Xi,Wei Xiong. Prognostic value of the long noncoding RNA AFAP1-AS1 in cancers. Oncol Transl Med, 2023, 9: 133-146. |
| 长链非编码RNA AFAP1-AS1在肿瘤中的预后价值 |
| Prognostic value of the long noncoding RNA AFAP1-AS1 in cancers |
| Received:June 14, 2022 Revised:May 29, 2023 |
| DOI：10.1007/s10330-022-0581-1 |
| 中文关键词: lncRNA,AFAP1-AS1,预后,荟萃分析 |
| 英文关键词: long noncoding RNA (lncRNA); actin filament-associated protein 1 antisense RNA 1 (AFAP1-AS1); prognostic; meta-analysis |
| 基金项目:云南省“万人计划”青年拔尖人才项目(无资助号) |
| Author Name | Affiliation | E-mail | | Lixiu Zhu* | Department of Radiotherapy, Yunnan Cancer Hospital, The Third Affiliated Hospital of Kunming Medical University, Yunnan 650000, China | 861354211@qq.com | | Jiawen Yan | Department of Radiotherapy, Yunnan Cancer Hospital, The Third Affiliated Hospital of Kunming Medical University, Yunnan 650000, China | | | Guoqiang Xu | Department of Radiotherapy, Yunnan Cancer Hospital, The Third Affiliated Hospital of Kunming Medical University, Yunnan 650000, China | | | Qiaoli Wang | Department of Radiotherapy, People''s Hospital of Yuxi City, The Sixth Affiliated Hospital of Kunming Medical University, Yunnan 653100, China | | | Tianrui Xu | Department of Radiotherapy, Yunnan Cancer Hospital, The Third Affiliated Hospital of Kunming Medical University, Yunnan 650000, China | | | Ruixue Cao | Department of Radiotherapy, Yunnan Cancer Hospital, The Third Affiliated Hospital of Kunming Medical University, Yunnan 650000, China | | | Chuanzheng Sun | Department of Head and Neck Surgery, Yunnan Cancer Hospital, The Third Affiliated Hospital of Kunming Medical University, Yunnan 650000, China | | | Yan Xi | Department of Head and Neck Surgery, Yunnan Cancer Hospital, The Third Affiliated Hospital of Kunming Medical University, Yunnan 650000, China | | | Wei Xiong | Department of Radiotherapy, Yunnan Cancer Hospital, The Third Affiliated Hospital of Kunming Medical University, Yunnan 650000, China | |
|
| Hits: 4660 |
| Download times: 7476 |
| 中文摘要: |
| 目的：本荟萃分析探讨AFAP1-AS1的表达是否与癌症患者的预后及临床病理特征相关。
方法：我们系统性地检索PubMed、EMBASE和Cochrane数据库。风险比（HRs）和95%置信区间（CIs）被用来评估基于总生存期（OS）,无病生存期（DFS）和无进展生存期（PFS）的预后价值。比值比（ORs）和95%置信区间（CIs）被用来确定AFAP1-AS1和临床病理特征之间的关系,如肿瘤大小（LTS）,肿瘤分期（HTS）、组织分级（PHG）、淋巴结转移（LNM）和远处转移（DM）。
结果：我们得到35篇合格的文献及3433例病例，并进行分析。AFAP1-AS1高表达患者的OS（HR=2.15, 95% CI=1.97-2.34, P<0.001）、DFS（HR=1.37, 95% CI=1.19-1.57, P<0.001）和PFS（HR=1.97, 95% CI=1.56-2.50, P<0.001）均显著低于AFAP1-AS1低表达患者。在多种肿瘤中，AFAP1-AS1表达升高与LTS（OR=2.76, 95% CI=2.16-3.53, P<0.001）、HTS（OR=2.23, 95% CI=1.83-2.71, P<0.001）和PHG（OR=1.39, 95% CI=1.08-1.79, P=0.01）显著相关，但是与LNM（OR=1.59, 95% CI=0.88-2.85, P=0.12）和DM（OR=1.81, 95% CI=0.90-3.66, P=0.10）无关。
结论：AFAP1-AS1高表达与预后和临床病理特征相关，提示AFAP1-AS1是人类癌症预后的生物标志物。 |
| 英文摘要: |
| Objective This meta-analysis explored whether the expression of actin filament-associated protein 1
antisense RNA 1 (AFAP1-AS1) is related to the prognosis and clinicopathological features of patients with
cancer.
Methods PubMed, EMBASE, and Cochrane Library were systematically searched. Hazard ratios (HRs)
with 95% confidence intervals (CIs) were used to assess the prognostic value based on overall survival
(OS), disease-free survival (DFS), and progression-free survival (PFS). Odds ratios (ORs) with 95% CIs
were used to determine the relationships between AFAP1-AS1 and clinicopathological features, such as
large tumor size (LTS), high tumor stage (HTS), poor histological grade (PHG), lymph node metastasis
(LNM), and distant metastasis (DM).
Results Thirty-five eligible articles and 3433 cases were analyzed. High AFAP1-AS1 expression,
compared to low AFAP1-AS1 expression, correlated with significantly shorter OS (HR = 2.15, 95% CI =
1.97–2.34, P < 0.001), DFS (HR = 1.37, 95% CI = 1.19–1.57, P < 0.001), and PFS (HR = 1.97, 95% CI
= 1.56–2.50, P < 0.001) in patients with cancer. In various cancers, elevated AFAP1-AS1 expression was
significantly associated with LTS (OR = 2.76, 95% CI = 2.16–3.53, P < 0.001), HTS (OR = 2.23, 95% CI =
1.83–2.71, P < 0.001), and PHG (OR = 1.39, 95% CI = 1.08–1.79, P = 0.01) but not LNM (OR = 1.59, 95%
CI = 0.88–2.85, P = 0.12) or DM (OR = 1.81, 95% CI = 0.90–3.66, P = 0.10).
Conclusion High AFAP1-AS1 expression was associated with prognostic and clinicopathological
features, suggesting that AFAP1-AS1 is a prognostic biomarker for human cancers. |
|
View Full Text
Download reader HTML全文 |
| Close |
|
|
|